158 related articles for article (PubMed ID: 3840407)
41. [Treatment of Hodgkin's disease. Experience of the Hôpital Saint-Louis].
Boiron M; Teillet F; Weisgerber C; Dana M; Jacquillat C; Bernard J
Rev Prat; 1974 Oct; 24(45):3971-8. PubMed ID: 4445767
[No Abstract] [Full Text] [Related]
42. Is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases?
Pavlidis N; Nikolaou N; Tolis C; Orfanos S; Tolis G
Med Pediatr Oncol; 1989; 17(3):222-6. PubMed ID: 2664441
[TBL] [Abstract][Full Text] [Related]
43. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
[TBL] [Abstract][Full Text] [Related]
44. [Second tumor following Hodgkin's disease].
Schmitt K; Tulzer W
Padiatr Padol; 1984; 19(3):259-62. PubMed ID: 6548008
[TBL] [Abstract][Full Text] [Related]
45. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
Valagussa P; Bonadonna G
Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571
[No Abstract] [Full Text] [Related]
46. The karyotype in secondary hematologic disorders after treatment for Hodgkin's disease. A study of 19 patients.
Iurlo A; Mecucci C; Van Orshoven A; Michaux JL; Boogaerts M; Van den Berghe H
Cancer Genet Cytogenet; 1988 Dec; 36(2):165-72. PubMed ID: 3203304
[TBL] [Abstract][Full Text] [Related]
47. Twenty years of MOPP therapy for Hodgkin's disease.
Longo DL; Young RC; Wesley M; Hubbard SM; Duffey PL; Jaffe ES; DeVita VT
J Clin Oncol; 1986 Sep; 4(9):1295-306. PubMed ID: 3528400
[TBL] [Abstract][Full Text] [Related]
48. [Acute leukemia in patients treated for Hodgkin's disease].
Boccaccio P; Rosa F; Casciaro S; D'Elia P; Romagnoli M; Ghio R
Recenti Prog Med; 1988 Jan; 79(1):32-7. PubMed ID: 3375542
[No Abstract] [Full Text] [Related]
49. [Advances in the chemotherapy of malignant lymphoma 1. Chemotherapy of Hodgkin's disease].
Suon SZ
Zhonghua Nei Ke Za Zhi; 1985 Feb; 24(2):117-120, contd. PubMed ID: 2580675
[No Abstract] [Full Text] [Related]
50. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.
Gobbi PG; Pieresca C; Federico M; Di Renzo N; Narni F; Iannitto E; Grignani G; Cavanna L; Avanzini P; Partesotti G
J Clin Oncol; 1993 Apr; 11(4):712-9. PubMed ID: 7683044
[TBL] [Abstract][Full Text] [Related]
51. Osteonecrosis of the femoral head following treatment for Hodgkin's disease.
Murray F; Daly PA; Freyne PJ
Ir J Med Sci; 1983 Jul; 152(7):286-8. PubMed ID: 6688611
[No Abstract] [Full Text] [Related]
52. [Hodgkin's disease in children; treatment results with or without radiotherapy].
van Bunningen BN; Dewit L; Bartelink H
Ned Tijdschr Geneeskd; 1986 May; 130(20):928-9. PubMed ID: 3755223
[No Abstract] [Full Text] [Related]
53. Radiation therapy is better than chemotherapy in early-stage Hodgkin's disease? Not so fast.
Longo DL; Duffey PL; Hubbard SM; Young RC; DeVita VT
J Clin Oncol; 1992 Aug; 10(8):1367-9. PubMed ID: 1634930
[No Abstract] [Full Text] [Related]
54. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie.
Noordijk EM; Carde P; Mandard AM; Mellink WA; Monconduit M; Eghbali H; Tirelli U; Thomas J; Somers R; Dupouy N
Ann Oncol; 1994; 5 Suppl 2():107-12. PubMed ID: 7515643
[TBL] [Abstract][Full Text] [Related]
55. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease.
Bossi G; Cerveri I; Volpini E; Corsico A; Baio A; Corbella F; Klersy C; Arico M
Ann Oncol; 1997; 8 Suppl 1():19-24. PubMed ID: 9187424
[TBL] [Abstract][Full Text] [Related]
56. [Chemotherapy of patients with Hodgkin's disease].
Onoshi T
Nihon Naika Gakkai Zasshi; 1994 Jun; 83(6):912-6. PubMed ID: 7964042
[No Abstract] [Full Text] [Related]
57. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
[TBL] [Abstract][Full Text] [Related]
58. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
59. [Controversy regarding the treatment of Hodgkin's disease].
Balwierz W; Armata J
Pol Tyg Lek; 1989 Apr; 44(14):315-9. PubMed ID: 2482966
[No Abstract] [Full Text] [Related]
60. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
